Cytek Biosciences Q2 EPS $(0.03) Misses $0.03 Estimate, Sales $49.69M Beat $45.71M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cytek Biosciences reported Q2 earnings per share (EPS) of $(0.03), missing the analyst consensus estimate of $0.03 by 200 percent. However, the company's quarterly sales of $49.69 million beat the estimate of $45.71 million by 8.71 percent.
August 08, 2023 | 10:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cytek Biosciences' Q2 EPS missed estimates significantly, but sales exceeded expectations.
Cytek Biosciences' Q2 earnings per share missed the analyst consensus estimate by a large margin, which could negatively impact investor sentiment and the stock price. However, the company's sales beat estimates, which could offset some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100